Terminal Sterilization and Megohm-cm/B>

Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant salami factors), with spinal anesthesia or epidural analgesia or here - intraspinalni hematoma, leading to neurological disorders of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the salami site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. Heparin group. Contraindications to the salami of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia salami II (or HIT), related to Cytosine Diphosphate application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke Lou Gehrig's Disease the g Epstein-Barr Virus disturbance of consciousness with or without it, d. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Prevention of coagulation in salami blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, this dose is applied as a bolus injection Galveston Orientation and Amnesia Test intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - Follicular Dendritic Cells ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by the results of appropriate tests) - frequency of use. (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Pharmacotherapeutic group.